ISSN: 0960-8931

Journal Home

Journal Guideline

Melanoma Research Q2 Unclaimed

Lippincott Williams and Wilkins Ltd. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Melanoma Research is a journal indexed in SJR in Oncology and Cancer Research with an H index of 80. It has an SJR impact factor of 0,633 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,633.

Melanoma Research focuses its scope in these topics and keywords: melanoma, patients, metastatic, patient, cutaneous, treated, survival, immune, imaging, human, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Dermatology (Q2) Cancer Research (Q3) Oncology (Q3)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,633

SJR Impact factor

80

H Index

69

Total Docs (Last Year)

249

Total Docs (3 years)

2717

Total Refs

440

Total Cites (3 years)

230

Citable Docs (3 years)

1.44

Cites/Doc (2 years)

39.38

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

International Journal of Oncology Q2
BMC Cancer Q2
Cancer Epidemiology Q2
Frontiers in Oncology Q2
Journal of Geriatric Oncology Q2

Compare this journals

Aims and Scope

Best articles by citations

Melanoma patient staging

Defining fast-growing melanomas

Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis

Detection of circulating melanoma cells in the blood of melanoma patients

IL-17, IL-23, and p73 expression in cutaneous melanoma

Loss of p16 expression is associated with histological features of melanoma invasion

Development and characterization of a murine monoclonal antibody against phaeomelanin and its precursor 5-S-cysteinyldopa

Animal-type malignant melanoma associated with nevus of Ota in the orbit of a Japanese woman

Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure

Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy

Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines

IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells

SHOW MORE ARTICLES

Protein kinases in normal and transformed melanocytes

Four cases of rituximab-associated melanoma

Akt and PI3K-dependent but CREB-independent upregulation of MCAM by endothelin-3 in human melanocytes

CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families

Integrin chains ??1 and ??v as prognostic factors in human metastatic melanoma

Increased expression of apoptotic markers in melanoma

CO20. Percutaneous hepatic perfusion (PHP) for metastatic melanoma

CO21. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

CO22. Long term outcomes after interstitial brachytherapy for lower lip carcinoma

CO23. The determinants of periorbital skin aging in a North European population

CO25. Suberoylanilide hydroxamic acid (Vorinostat) plus Mithramycin A (Plicamycin) treatments in Sezary lymphoma

CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients